Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blue dye tested in septic shock: could it help ICU patients?

NCT ID NCT06900140

Disease control Sponsor: Dr. Shannon M. Fernando Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether adding methylene blue to standard care is feasible for adults with septic shock in the intensive care unit. The main goal was to see if a larger trial could be done, not to prove the treatment works. Fifty patients took part, and the study looked at how many could be enrolled and how well they followed the treatment plan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

50 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (≥ 18 years of age) admitted to the ICU 2. Diagnosed with septic shock (as per the Sepsis-3 Criteria): Suspected infection (i.e. initiation of antimicrobial therapy), coupled with initiation of vasopressor therapy to target a mean arterial pressure (MAP) \> 65 mmHg (or as prescribed by the treating clinician), after adequate fluid resuscitation (as per treating clinician). 3. Minimal norepinephrine dose of 0.1 mcg/kg/min for a minimum of 2 hours at the time of enrollment (i.e., the time of randomization). Exclusion Criteria: 1. \> 48 hours since initiation of norepinephrine 2. \> 48 hours since admission to ICU 3. Anticipation of discontinuation of vasopressors in \< 24 hours 4. Pregnancy \*\*Women of childbearing age (\<50 years) should have a urine or beta hCG performed prior to enrolment 5. Plan for withdrawal of life support 6. Concurrent hemorrhagic, obstructive, or hypovolemic shock 7. Major burn injury (\>10% total body surface area) 8. Known Personal or familial history of glucose-6-phophate dehydrogenase deficiency 9. Known Allergy to methylene blue, phenothiazines, or food dyes 10. Known recent intake of selective serotonin re-uptake inhibitors (21 days for norfluoxetine, and 14 days for any other SSRI). 11. Currently receiving linezolid

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Septic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Septic shock

Contacts and locations

Locations

  • Lakeridge Health Ajax-Pickering

    Ajax, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.